- Company to harness data and advanced medical technologies to deliver innovative solutions in healthcare
- Building sustainable models with public-private partnerships
Dubai, United Arab Emirates: G42 Healthcare, a leading health-tech company on a mission to develop a world-class healthcare sector in the UAE and beyond, will showcase state-of-the-art digital solutions to transform the UAE’s healthcare and life sciences ecosystem at the Arab Health 2021 and Medlab Middle East from June 21 to June 24 at the Dubai World Trade Centre.
This includes G42 Healthcare’s latest AI platforms, scientific research and cutting-edge technology in genomics, digital health, diagnostics, and clinical trials to bring new healthcare solutions to communities and futureproof the health of nations.
During Arab Health, G42 Healthcare will share learnings from the 4Humanity clinical trials, the world’s first Phase III clinical trials of an inactivated vaccine, as well as discuss other initiatives, such as wastewater analysis to study the spread of infectious diseases, COVID-19 tracking and testing and other disruptive solutions to build an integrated healthcare response beyond the current pandemic.
At Medlab Middle East, G42 Healthcare will be showcasing its capabilities in genome sequencing, partnerships in the domain of molecular diagnostics, digitisation, and research programmes. The company will also highlight its futuristic projects currently underway at Biogenix Labs, the UAE’s first COVID-19 accredited large-scale detection laboratory and the Omics Centre of Excellence, the region’s largest and technologically advanced multi-omics facility. These include comprehensive detection and diagnosis solutions to fight COVID-19, the latest advancements in healthcare and artificial intelligence research, as well as an overview on the Emirati Genome Programme.
G42 Healthcare will also take centre stage on various panel discussions at the conferences. Ashish Koshy, CEO of G42 Healthcare, will speak on ‘An Integrated Healthcare Response: Beyond COVID-19’ on June 23 while Dr Walid Zaher, Chief Research Officer and Vaccine Project Lead at G42 Healthcare, will speak on ‘Learnings from 4Humanity: A MENA Experience’ on June 21. Dr Fahed Al Marzooqi, COO of G42 Healthcare, will speak on ‘Prioritising Public-Private-Partnerships to Build Sustainable Models for Futureproofing Healthcare’ at a panel discussion on June 24.
Speaking about G42 Healthcare’s participation, Ashish Koshy, CEO of G42 Healthcare said: “G42 Healthcare is delighted to debut its participation at Arab Health and Medlab Middle East. The COVID-19 pandemic has shown how we can come together as an industry to accelerate innovation, and we continue to see the positive impact of technology on patient care. The future of the healthcare sector will be data-driven, digitised, value-based and more precise – and these events offer a great opportunity to present our perspective and showcase our expertise to a wider audience, and learn from our peers.”
Talking about partnerships, he said: “G42 Healthcare is looking forward to partner and share best practices with governments, leading international entities, scientists and researchers and the wider medical community who subscribe to its values and mission aimed at developing solutions to futureproof the health of nations.”
At Arab Health, G42 Healthcare will also participate in a CEO networking session on June 23 to discuss possibilities in health-tech and cement fruitful collaborations with its partners and stakeholders.
About G42 Healthcare
G42 Healthcare, a leading health-tech company, is on a mission to develop a world-class healthcare sector in the UAE and beyond, by harnessing data and advanced medical technologies to unlock the potential of personalized and preventive care and transforming the traditional healthcare ecosystem.
At the forefront in the battle against COVID-19, we have established Biogenix Labs, UAE’s first COVID-19 accredited large-scale throughput laboratory, facilitated the 4Humanity clinical trials, the world’s first phase three trial for inactivated vaccine against COVID-19 with over 43,000 volunteers from 125+ nationalities across the pan-Arab region, supported UAE’s healthcare authorities on the national vaccination implementation, employed advanced AI techniques and vast computing resources to accelerate the detection of COVID-19, conducted research into new vaccines and drug therapies, and built Omics Centre of Excellence, the region’s largest and most technologically advanced omics facility that is the backbone for the Emirati Genome Program, the world’s most comprehensive population genomics initiative.
Beyond COVID-19 we have plans and R&D encompassing genomics, imaging and diagnostics, and digitization programs to support the health of future generations. At G42 Healthcare, our plans are large in scale and bold in ambition. We partner extensively with governments, leading international entities, scientists and researchers and the wider medical community who subscribe to our values and our mission as we develop solutions to future-proof the health of nations.
Visit the G42 Healthcare stand Z4.B10 from 21st – 24th June 2021.
